首页> 外文期刊>Drug development and industrial pharmacy >Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: Ex-vivo transcorneal permeation, corneal toxicity and irritation testing
【24h】

Design and development of a novel pH triggered nanoemulsified in-situ ophthalmic gel of fluconazole: Ex-vivo transcorneal permeation, corneal toxicity and irritation testing

机译:氟康唑新型pH触发纳米乳化原位眼用凝胶的设计和开发:离体透角膜渗透,角膜毒性和刺激性测试

获取原文
获取原文并翻译 | 示例
           

摘要

The objective of the present research was to develop a novel pH triggered nanoemulsified in-situ gel (NE-ISG) for ophthalmic delivery of fluconazole (FLZ) to enhance the permeation and residence time of the formulation, by overcoming the limitations associated with protective ocular barriers. Pseudoternary phase diagrams were constructed using capmul MCM (oil phase), tween 80 (surfactant) and transcutol P (cosurfactant) to identify the NE region. Nanoemulsions (NE1-NE6) of FLZ were prepared by spontaneous emulsification method and evaluated for various pharmacotechnical characteristics. NE4 was selected as optimized NE and was dispersed in carbopol 934 solution to form nanoemulsified sols (NE-ISG1 to NE-ISG5) that were expected to convert in to in-situ gels at corneal pH (7.4). The optimized NE-ISG was selected on the basis of gelation ability with a residence time up to or more than 6 h. Ex-vivo transcorneal permeation study displayed significantly higher (p0.05) permeation of FLZ from NE-ISG5 (337.67 μg/cm2) and NE4 (419.30 μg/cm2) than the commercial eye drops (112.92 μg/cm2). Hen's egg test-Chorioallantoic membrane (HET-CAM) test with zero score indicated the non-irritant property of developed NE-ISG5. Corneal toxicity study revealed no visual signs of tissue damage. Hence it can be concluded that NE-ISG5 may offer a more intensive treatment of ocular fungal infections due to higher permeation, prolonged precorneal residence time and sustained drug release along with higher in-vitro efficacy, safety and greater patient compliance.
机译:本研究的目的是通过克服与保护性眼药水有关的局限性,开发一种新型的pH触发纳米乳化原位凝胶(NE-ISG),以眼科方式输送氟康唑(FLZ),以提高制剂的渗透和停留时间。障碍。使用capmul MCM(油相),吐温80(表面活性剂)和transcutol P(辅助表面活性剂)构建伪三元相图,以识别NE区。通过自发乳化法制备了FLZ纳米乳液(NE1-NE6),并对其各种药理特性进行了评估。选择NE4作为优化的NE,并将其分散在carbopol 934溶液中以形成纳米乳化溶胶(NE-ISG1至NE-ISG5),有望在角膜pH值(7.4)下转化为原位凝胶。基于凝胶化能力选择最优化的NE-ISG,其停留时间长达或超过6小时。体外透角膜渗透研究显示,NE-ISG5(337.67μg/ cm2)和NE4(419.30μg/ cm2)的FLZ渗透率明显高于商业滴眼液(112.92μg/ cm2)(p <0.05)。零分的鸡蛋鸡蛋测试-尿囊化膜(HET-CAM)测试表明已开发的NE-ISG5无刺激性。角膜毒性研究显示无视觉损伤迹象。因此可以得出结论,由于较高的渗透性,延长的角膜前停留时间和持续的药物释放以及更高的体外疗效,安全性和更大的患者依从性,NE-ISG5可以提供更深入的眼真菌感染治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号